Norethisterone acetate transdermal - Pierre Fabre

Drug Profile

Norethisterone acetate transdermal - Pierre Fabre

Latest Information Update: 15 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amarin Corporation
  • Class Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 01 Apr 2008 Discontinued - Preregistration for Menopausal syndrome in France (Transdermal)
  • 17 Jun 2003 No development reported - Preregistration for Menopausal syndrome in France (Transdermal)
  • 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top